Erratum to: Post-herpetic Neuralgia: a Review

Abstract

The authors would like to point out that on the right hand column on page 3, lastparagraph, lines 3-6 in the original version, the sentence has an error. The correct sentence should read: Traditional gabapentin saturates transporters only in a limited part of the small intestine, while enacarbil has the ability to employ high-capacity nutrient transporters along the entirety of the small and large intestine.On page 17 of the orginal version, in the second paragraph, the sentence that states: BThe oral bioavailability of pregabalin is quite high at over 90 % when taken at 900 mg/day but decreases to 27 % when doses exceed 4800 mg/day [35••, 43].^contains a mistake. The word Bpregabalin^should be corrected to Bgabapentin^. The sentence should read: BThe oral bioavailability of gabapentin is quite high at over 90 % when taken at 900 mg/day but decreases to 27 % when doses exceed 4800 mg/day [35••, 43].^

Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain

“…No patient referred radiating distribution in other body regions. Moreover, we reported that, in NeP group, our translated version of PD-Q was Pain Research and Management able to identify the pain course pattern specific of the neuropathic syndromes included in our study (trigeminal neuralgia and postherpetic pain) according to descriptors found in literature [10,11]. Finally, the good concordance rate between the reference diagnosis and the mean value of LANSS confirmed that our translated version of the questionnaire may be considered a useful screening tool in daily clinical routine and in the therapeutic management of this insidious kind of pain.…”

“…No patient referred radiating distribution in other body regions. Moreover, we reported that, in NeP group, our translated version of PD-Q was able to identify the pain course pattern specific of the neuropathic syndromes included in our study (trigeminal neuralgia and postherpetic pain) according to descriptors found in literature [ 10 , 11 ].…”

“…e PD-Q was originally developed for people with low-back pain and showed good sensitivity (85%) and specificity (80%) when compared to clinical diagnosis of a predominantly nociceptive (e.g., visceral-pain) or neuropathic (e.g., postherpetic neuralgia) origin [3]. e PD-Q classifies people into different groups according to a summative score from nine-items: NeP component is unlikely (≤12), result is ambiguous [8][9][10][11][12][13], and NeP component is likely (≥19). Most items use a 6-point scale, where higher scores are suggestive of greater intensity.…”

Efficacy and safety of twice‐daily tramadol hydrochloride bilayer sustained‐release tablets with an immediate release component for postherpetic neuralgia: Results of a Phase III, randomized, double‐blind, placebo‐controlled, treatment‐withdrawal study

“…19 We chose a minimum of 3 months to indicate that the patient was suffering from chronic rather than acute pain, and ensure that the pain was intractable to conventional therapies and hence be a candidate for opioid treatment; this duration was also used to define PHN in earlier reports. 20,21 Exclusion criteria included the following: presence of another disorder causing pain that was colocalized with the herpes zoster lesions; comorbidities associated with chronic pain that was likely to affect efficacy evaluations; pain that was suspected of being psychogenic in origin; the investigator believed the cause of pain would interfere with…”